The holistic impact of oncotype DX for patients with an intermediate risk breast cancer: A single centre experience

Aim: Oncotype DX is a NICE approved genomic test for patients who have intermediate risk breast cancer. It provides a ten year distant recurrence risk which provides additional information when considering adjuvant chemotherapy benefits. Few studies have looked at the relationship between the Oncotype DX and Nottingham Prognostic Indicator and we note there is less evidence exploring the impact Oncotype DX makes to patients holistically.
Source: International Journal of Surgery - Category: Surgery Authors: Source Type: research